tbuckley/cabot-search huggingface dataset:
P04.03 Analysis of the inflammatory tumor microenvironment in meningeal malignancies
Authors: A. S. Berghoff, P. Kresl, O. Rajky, G. Widhalm, G. Ricken, J. Hainfellner, C. Marosi, C. C. Zielinski, P. Birner, M. Preusser
Journal: Neuro-Oncology (2016)

INTRODUCTION:The treatment of glioblastoma multiforme (GBM) is a major challenge of neuro-oncology.Despite aggressive therapeutic strategies including surgery and radio-chemotherapy, median survival remains extremely low.This points to the urgent need for alternative treatment strategies such as immunotherapy.Immunological escape mechanisms, involving the Natural Killer Group 2, member D (NKG2D) receptor-ligand system, play a major role in tumor progression.Cell-bound NKG2D-ligands such as MHC class I related molecule A and B (MICA and MICB), and the UL-16 binding protein family (ULBP1-6) are recognized by the NKG2D-receptor (NKG2Dr) and trigger cytotoxic effector functions in NK-cells and T-cell subsets.By releasing soluble NKG2DL (sNKG2DL), which then bind to NKG2Dr, tumor cells inhibit the killing potential of the effector cells.Numerous studies documented the importance of NKG2D-system in vitro GBM-model systems.Here, we aimed to analyze NKG2D-system in GBM-patients ex vivo.MATERIALS AND METHODS: Until now, 37 GBM patients and 19 healthy controls (HCs) have been included in the study.A total of 24 GBM patients were on medication with dexamethasone prior to surgery.We analyzed serum levels of sNKG2DLs in HCs and GBM patients before and 3 months after surgery and radio-chemotherapy via Luminex-based multiplex assay.Absolute cell numbers of distinct immune cell subsets and the expression of NKG2Dr were analyzed by flow cytometry.NKG2DLexpression on GBM primary cell cultures was studied via flow cytometry and western-blotting.RESULTS: Our data show that in comparison to healthy controls GBM patients show reduced numbers of leukocytes and cytotoxic effector cells in peripheral blood, but elevated numbers of immunosuppressive cell subsets.Whereas NKG2Dr is not detectable in primary cell cultures, the tumor cells moderately express NKG2DL and release sNKG2DL into the culture medium.Serum levels of sNKG2DL are differentially modulated in GBM patients when comparing pre-to 3 months postop.This effect is independent of medication with dexamethasone.CONCLUSION: GBM patients seem to have impaired cytotoxic immune response compared to HCs.As NKG2DL are released by the tumor cells, this effect might also be generated via sNKG2DL.Nevertheless, serum levels of NKG2DL do not decline after treatment in most patients.A better understanding of the mechanisms regulating the NKG2D-system in GBM patients will be crucial for the development of new therapeutic strategies targeting the NKG2D system.
Coffee Consumption and Risk of Gallbladder Cancer in a Prospective Study
Authors: Susanna C. Larsson, Edward L. Giovannucci, Alicja Wolk
Journal: JNCI Journal of the National Cancer Institute (2016)

Evidence indicates that coffee consumption may reduce the risk of gallstone disease, which is strongly associated with increased risk of gallbladder cancer. The association between coffee consumption and gallbladder cancer incidence was examined in a prospective cohort study of 72 680 Swedish adults (aged 45 - 83 years) who were free of cancer and reported their coffee consumption at baseline. Gallbladder cancers were ascertained by linkage with the Swedish Cancer Register. The data were analyzed using Cox proportional hazards regression models. Statistical tests were two-sided. During 967 377 person-years of follow-up, 74 gallbladder cancer case patients were identified. Compared with consumption of one or less cups of coffee per day, the multivariable hazard ratios were 0.76 (95% confidence interval [CI] = 0.41 to 1.41) for two cups per day, 0.50 (95% CI = 0.24 to 1.06) for three cups per day, and 0.41 (95% CI = 0.20 to 0.83) for four or more cups per day. In conclusion, coffee consumption is associated with a reduced risk of gallbladder cancer.
Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results.
Authors: Franck Morschhauser, John P. Leonard, Luis Fayad, Bertrand Coiffier, STephen J. Schuster, Martin J.S. Dyer, Marie-Odile Petillon, Morton Coleman, Amina Bahkti, Heather Horne, Li Xu, Nick Teoh, William A. Wegener, David M. Goldenberg
Journal: Blood (2006)
Maternal DNA Methylation in Second Half of Pregnancy in Th1, Th2, Th17 and Treg Pathway Genes Differs with Birth-Order
Authors: Orpita Nilormee, Gabrielle A. Lockett, Sabrina Iqbal, John W. Holloway, Syed H. Arshad, Hongmei Zhang, Wilfried Karmaus
Journal: Journal of Allergy and Clinical Immunology (2017)
Salvage Therapy for Multiple Myeloma with Lenalidomide-Based Regimens: Impact of Single Nucleotide Polymorphisms Related to miRNA Pathways
Authors: Carlos Fernández de Larrea, Tania Díaz, María Teresa Cibeira, Natalia Tovar, Alfons Navarro, Laura Rosiñol, Raquel Jiménez, Rut Tejero, Mariano Monzó, Joan Bladé
Journal: Blood (2014)
CSIG-11. ROLE OF OLIG2 PARTNER PROTEINS IN GLIOBLASTOMA
Authors: Costanza LoCascio, Robert Kupp, Shiv Singh, Emily Szeto, Vincent Loo, Femina Rauf, Alanna Derogatis, Joshua Labaer, Nader Sanai, Shwetal Mehta
Journal: Neuro-Oncology (2016)

OLIG2 is a central nervous system specific transcription factor that is expressed in almost all diffuse gliomas. It is also one of the key core transcription factors that can reprogram differentiated glioma cells to highly tumorigenic glioma stem-like cells. We have previously shown that expression of OLIG2 is critical for glioma growth both in a genetically relevant mouse model as well as in patient-derived xenograft models. It is the phosphorylated form of OLIG2 (S10, S13 and S14) that is responsible for its pro-mitogenic functions. We have recently shown that OLIG2 interacts with distinct proteins based in its post-translational modifications. In an effort to identify direct interacting co-regulatory proteins of OLIG2 under oncogenic conditions we employed a novel proteomics screen, NAPPA (Nucleic Acid Programmable Protein Arrays). Using NAPPA analysis we have not only identified known interactors of OLIG2 (e.g., OLIG1, SALL2, p300 and HDAC1) but also novel interactors that have not been previously described. Here, we demonstrate how OLIG2 partners with distinct proteins to either promote proliferation or invasion in glioma stem-like cells based on its phosphorylation state. Furthermore, we provide evidence that targeting (genetic or pharmacological) of druggable OLIG2 partner proteins either alone or in combination with standard-of-care leads to significant decrease in growth of patient-derived xenograft models, both in vitro and in vivo.
Recombinant Human C1 Inhibitor (rHC1INH) Is Efficacious and Well Tolerated As Prophylaxis for Prevention of Hereditary Angioedema (HAE) Attacks: A Randomized, Phase 2 Trial
Authors: William H. Yang, H.H. Li, Chevy Chase, D. Moldovan, V. Grivcheva-Panovska, J.R. Harper, A. Relan, Marc A. Riedl
Journal: Journal of Allergy and Clinical Immunology (2017)
Assessment of Mutation Status in a Large Series of Patients with Cytopenias with Normal Karyotypes and without Increased Blasts
Authors: Lobin A Lee, Yongbao Wang, Russell Maiese, Kevin J Arvai, Qiulu Pan, Kumudini Mehta, Sean M Caruthers, Steven L Gersen, Shere Billouin-Frazier, Frederick Karl Racke, Dan Jones
Journal: Blood (2014)
PML/RARα -Regulated MicroRNA 181b Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia
Authors: Daniela Braeuer-Hartmann, Jens-Uwe Hartmann, Dennis Gerloff, Christiane Katzerke, Maria Vittoria Verga Falzacappa, Pier Guiseppe Pellicci, Carsten Mueller-Tidow, Daniel G. Tenen, Dietger Niederwieser, Gerhard Behre
Journal: Blood (2011)
Genomic profile in pulmonary neuroendocrine tumors (puNETs): the whole-exome sequencing (WES) as a strategic tool
Authors: I.G. Sullivan, M. Deloger, L. Lacroix, B. Job, N. Dorvault, J. Adam, A. Honore, L. Gianoncelli, G. Le Teuff, V. de Montpreville, B. Besse, J.-C. Soria, J.-Y. Scoazec, E. Baudin, D. Planchard
Journal: Annals of Oncology (2016)
Characteristics and Outcome of MDS with Isolated Del 20q: The GFM Experience in 64 Cases.
Authors: Thorsten Braun, Stephane de Botton, Anne-Laure Taksin, Sophie Park, Odile Beyne-Rauzy, Sylvie Chevret, Michaela Fontenay, Bruno Cassinat, Anne Lazareth, Virginie Eclache, Chrisitine Terre, Norbert Vey, Agnes Guerci, Francois Dreyfus, Dominique Bordessoule, Aspasia Stamatoullas, Sylvie Castaigne, Pierre Fenaux, Lionel Ades
Journal: Blood (2008)
Development of a collaborative improvement network by a state affiliate of the American Society of Clinical Oncology.
Authors: Andrew Allan Hertler, Denis Brin Hammond, Steven S. Larmon, Thomas H. Openshaw, Christian Thomas, Tracey Weisberg
Journal: Journal of Clinical Oncology (2012)

79 Background: Participation in the Quality Oncology Practice Initiative (QOPI) by members of the Northern New England Oncology Society (NNECOS) has been historically low (two practices consistently participating). A survey of members identified a lack of resources (time, personnel, financial) as the principal obstacles. In alignment with NNECOS’ mission “To assure the availability of and access to high quality oncology care in our region,” NNECOS sought to determine if it could establish a Collaborative Improvement Network (CIN) in which 1) experienced practices mentor inexperienced practices in QOPI, and 2) practices benchmark results against each other, sharing best practices. Methods: Six practices from the NNECOS member states of Maine, New Hampshire, and Vermont agreed to join the CIN and participate in the fall 2010 and spring 2011 QOPI data collection. Meetings were held following each QOPI data collection and blinded results were compared. High achievers on individual metrics shared their processes/tools with all the participants in the CIN. Results: To develop consistency in data collection, a joint training program for abstractors was developed. There was rapid agreement to eliminate the blinding of results, allowing candid discussions about the barriers to success and strategies for overcoming those barriers. The following tools that successful practices had used were shared: a “one page chemotherapy treatment summary,” chemotherapy consent forms, an oral chemotherapy procedure, and a “chair-side smoking cessation program.” Interventions piloted included a “hardwired chemotherapy treatment summary” and a “hardwired intervention for emotional distress.” Improvement was seen in “plan of care for severe pain” (72% to 85%), “signed consent for chemotherapy” (59% to 81%), and “infertility risk discussions” (14% to 35%). The CIN continues to operate, with 8 of the 17 practices in the three states participating. It is currently engaged in a project to implement specific performance improvement processes for end-of-life care. Conclusions: We have shown that it is possible for an ASCO State Affiliate to sponsor and develop a CIN.
Interphase Fluoroscence in Situ Hybridization Improves the Detection Rate of CNS Involvement in Childhood Acute Lymphoblastic Leukemia.
Authors: Seungman Park, Sangho Lee, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn, Hyun Kyung Kim, Dong Soon Lee, Han Ik Cho
Journal: Blood (2009)
Risk Stratification for Sudden Cardiac Death After Myocardial Infarction
Authors: Jonathan W. Waks, Alfred E. Buxton
Journal: Annual Review of Medicine (2018)

Sudden cardiac death (SCD) accounts for ∼50% of mortality after myocardial infarction (MI). Most SCDs result from ventricular tachyarrhythmias, and the tachycardias that precipitate cardiac arrest result from multiple mechanisms. As a result, it is highly unlikely that any single test will identify all patients at risk for SCD. Current guidelines for use of implantable cardioverter-defibrillators (ICDs) to prevent SCD are based primarily on measurement of left ventricular ejection fraction (LVEF). Although reduced LVEF is associated with increased total cardiac mortality after MI, the focus of current guidelines on LVEF omits ∼50% of patients who die suddenly. In addition, there is no evidence of a mechanistic link between reduced LVEF and arrhythmias. Thus, LVEF is neither sensitive nor specific as a tool for post-MI risk stratification. Newer tests to screen for predisposition to ventricular arrhythmias and SCD examine abnormalities of ventricular repolarization, autonomic nervous system function, and electrical heterogeneity. These tests, as well as older methods such as programmed stimulation, the signal-averaged electrocardiogram, and spontaneous ventricular ectopy, do not perform well in patients with LVEF ≤30%. Recent observational studies suggest, however, that these tests may have greater utility in patients with LVEF >30%. Because SCD results from multiple mechanisms, it is likely that combinations of risk factors will prove more precise for risk stratification. Prospective trials that evaluate the performance of risk stratification schema to determine ICD use are necessary for cost-effective reduction of the incidence of SCD after MI.
543P Thromboembolism in gastrointestinal tract cancer patients receiving chemotherapy: Preplanned analysis of risk factors and survival
Authors: A. Oba, M. Nakamura, T. Murai, C. Matsuda, K. Itaya, Y. Koike, A. Endo, Y. Tsukuda, Y. Ono, T. Kudo, A. Nagasaka, S. Nishikawa
Journal: Annals of Oncology (2016)
A mechanism of action study of intra-tumoral or intravenous dosing of enadenotucirev, an oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma undergoing resection of primary tumor
Authors: R. Garcia-Carbonero, V. Boni, I. Duran, M. Gil, M. Espinosa, R. Salazar, A. Cubillo, M. Jurado, B. Champion, S. Alvis, K. Fisher, J. Beadle, G. Pover, H. McElwaine-Johnn, C. Ellis, C. Blanc, E. Calvo
Journal: Annals of Oncology (2016)
Prevalence and Clinical Attributes of Congenital Microcephaly — New York, 2013–2015
Authors: Krishika A. Graham, Deborah J. Fox, Achala Talati, Cristian Pantea, Laura Brady, Sondra L. Carter, Eric Friedenberg, Neil M. Vora, Marilyn L. Browne, Christopher T. Lee
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Congenital Zika virus infection can cause microcephaly and other severe fetal neurological anomalies (1). To inform microcephaly surveillance efforts and assess ascertainment sources, the New York State Department of Health and the New York City Department of Health and Mental Hygiene sought to determine the prevalence of microcephaly in New York during 2013-2015, before known importation of Zika virus infections. Suspected newborn microcephaly diagnoses were identified from 1) reports submitted by birth hospitals in response to a request and 2) queries of a hospital administrative discharge database for newborn microcephaly diagnoses. Anthropometric measurements, maternal demographics, and pregnancy characteristics were abstracted from newborn records from both sources. Diagnoses were classified using microcephaly case definitions developed by CDC and the National Birth Defects Prevention Network (NBDPN) (2). During 2013-2015, 284 newborns in New York met the case definition for severe congenital microcephaly (prevalence = 4.2 per 10,000 live births). Most newborns with severe congenital microcephaly were identified by both sources; 263 (93%) were identified through hospital requests and 256 (90%) were identified through administrative discharge data. The proportions of newborns with severe congenital microcephaly who were black (30%) or Hispanic (31%) were higher than the observed proportions of black (15%) or Hispanic (23%) infants among New York live births. Fifty-eight percent of newborns with severe congenital microcephaly were born to mothers with pregnancy complications or who had in utero or perinatal infections or teratogenic exposures, genetic disorders, or family histories of birth defects.
MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network
Authors: Christiane Pott, Elizabeth Macintyre, Marie-Helene Delfau-Larue, Vincent Ribrag, Michael Unterhalt, Michael Kneba, Wolfgang Hiddemann, Martin Dreyling, Olivier Hermine, Eva Hoster
Journal: Blood (2014)
Fatigue and sleep in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)
Authors: D. A. Mulrooney, A. C. Mertens, J. P. Neglia, D. M. Green, L. Zeltzer, L. L. Robison
Journal: Journal of Clinical Oncology (2004)

8129 Background: Fatigue has been reported as a late effect of cancer therapy. Limited data are available assessing fatigue and sleep among large populations of long-term survivors of pediatric and adolescent cancer. Methods: The CCSS is a cohort of 5+ yr survivors diagnosed with cancer before age 21, between 1970–1986. A selected sample of CCSS participants (lymphoblastic leukemia (ALL), brain tumors (CNS), Hodgkin's disease (HD), soft-tissue sarcoma (STS), bone tumors) was surveyed regarding self-reported fatigue and sleep using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; range 0–52; higher score=lower fatigue), the Epworth Sleepiness Scale (ESS; range 0–24; higher score=higher daytime sleepiness), and the Pittsburgh Sleep Quality Index (PSQI; range 0–21; higher score=poorer sleep quality). Results: Data were available from 981 participants (43% males, 57% females) whose mean age at diagnosis was 12.4 yrs and 33.9 yrs at follow-up. Survivors scored higher, compared to population norms, on the FACIT-F (40.4 vs. 36.8, p<0.001), ESS (6.3 vs. 5.9, p<0.001), and PSQI (6.2 vs. 2.7, p<0.001), suggesting greater sleep disturbance without greater fatigue. While there were statistically significant differences among diagnostic groups, clinical significance is doubtful.(Table) Males and females did not demonstrate significant differences on the ESS or PSQI scores, but did differ significantly on the FACIT-F score (42.3 vs. 39.1, p<0.001). Conclusion: This interim analysis showed that long-term survivors of childhood cancer did not report increases in fatigue compared to general population norms, even though 57.6% of survivors reported poor sleep quality (PSQI>5). No significant financial relationships to disclose.
Conserved Fever Pathways across Vertebrates: A Herpesvirus Expressed Decoy TNF-α Receptor Delays Behavioral Fever in Fish
Authors: Krzysztof Rakus, Maygane Ronsmans, Maria Forlenza, Maxime Boutier, M. Carla Piazzon, Joanna Jazowiecka-Rakus, Derek Gatherer, Alekos Athanasiadis, Frédéric Farnir, Andrew J. Davison, Pierre Boudinot, Thomas Michiels, Geert F. Wiegertjes, Alain Vanderplasschen
Journal: Cell Host & Microbe (2017)

Both endotherms and ectotherms (e.g., fish) increase their body temperature to limit pathogen infection. Ectotherms do so by moving to warmer places, hence the term "behavioral fever." We studied the manifestation of behavioral fever in the common carp infected by cyprinid herpesvirus 3, a native carp pathogen. Carp maintained at 24°C died from the infection, whereas those housed in multi-chamber tanks encompassing a 24°C–32°C gradient migrated transiently to the warmest compartment and survived as a consequence. Behavioral fever manifested only at advanced stages of infection. Consistent with this, expression of CyHV-3 ORF12, encoding a soluble decoy receptor for TNF-α, delayed the manifestation of behavioral fever and promoted CyHV-3 replication in the context of a temperature gradient. Injection of anti-TNF-α neutralizing antibodies suppressed behavioral fever, and decreased fish survival in response to infection. This study provides a unique example of how viruses have evolved to alter host behavior to increase fitness.
Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
Authors: J. Balmaña, C. Cruz, B.K. Arun, M. Telli, J. Garber, S. Domchek, C.M. Fernandez, C. Kahatt, S. Szyldergemajn, A. Soto-Matos, A. Perezdela Haza, J.A. Perez Fidalgo, A. Lluch-Hernandez, S. Antolin, N.M. Tung, L.T. Vahdat, R. Lopez, S.J.J. Isakoff
Journal: Annals of Oncology (2016)
Allogeneic Stem Cell Transplantation for Relapsed Hodgkin’s Disease - a Single Centre Experience
Authors: Christof Scheid, Peter Borchmann, Henning Bredenfeld, Jens Chemnitz, Udo Holtick, Birgit Cremer, Michael Bergwelt-Baildon, Michael Hallek, Andreas Engert
Journal: Blood (2008)
Patterns of diagnostic imaging and cumulative radiation exposure among long-term young adult cancer survivors.
Authors: Corinne Daly, David Urbach, Therese A. Stukel, Wayne Deitel, Paul C. Nathan, Lawrence Frank Paszat, Nancy N. Baxter
Journal: Journal of Clinical Oncology (2012)

6027 Background: Young adults surviving a diagnosis of malignancy have a considerable life expectancy, however, little is known about radiation exposure from diagnostic imaging in these patients. This study aims to describe patterns of imaging and radiation exposure in young adult cancer survivors (YAS) and cancer-free controls in Ontario, Canada. Methods: We conducted a population-based retrospective study. Young adults aged 20-44 diagnosed with an invasive malignancy between 1992 and 1999 who lived at least 5 years without recurrent disease were identified in the Ontario Cancer Registry. YAS were matched 1:5 to randomly selected cancer-free controls on calendar year of birth, sex, and geographic location. Radiological procedures were identified through Ontario Health Insurance Plan administrative data. The rate at which individuals underwent diagnostic procedures after surviving 5-years was compared between survivors and controls using Poisson regression. Cumulative radiation exposure due to computed tomography (CT) and standard x-ray were calculated. Results: 20,911 YAS and 104,524 controls had a median of 13.5 years observation time after cancer diagnosis/referent date. The rate of CT scanning after 5 year survival was higher in YAS (rate ratio= 3.59, 95% CI: 3.46 – 3.73) and varied according to malignancy type (Table). Over the course of diagnosis, treatment and surveillance to 10 years, the average YAS was exposed to 33.8 mSv of radiation, 4.4 times the radiation exposure an individual in the general population received. 47% of YAS cumulative dose was attributed to exposure 5 years or more after diagnosis. Conclusions: YAS undergo imaging and are exposed to diagnostic irradiation at a significantly higher rate than controls even after 5 years of recurrence free survival. Alternative imaging techniques not associated with exposure to radiation should be considered for these patients. [Table: see text]
Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.
Authors: Richard H. Ko, Lingyun Ji, Richard Sposto, Phillip Barnette, Bruce Bostrom, Raymond Hutchinson, Elizabeth Raetz, Nita Seibel, Clare Twist, Elena Eckroth, Paul Gaynon, Mignon Loh
Journal: Blood (2007)
Skewing towards Decreased Fc-Fucosylation of Platelet-Alloantibodies in Pregnancy
Authors: Rick Kapur, Anne Vestrheim, Carolien AM Koeleman, Leendert Porcelijn, Dave Jackson, Belinda Kumpel, André M Deelder, Terje E Michaelsen, Masja de Haas, C. Ellen Van der Schoot, Manfred Wuhrer, Gestur Vidarsson
Journal: Blood (2012)
Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.
Authors: Jennifer L. Kelly, Gilles Salles, Bryan H. Goldman, Richard I Fisher, Olivier Casasnovas, Oliver W. Press, David G. Maloney, Pierre Soubeyran, Lisa M. Rimsza, Michael LeBlanc, Herve Tilly, Jonathan W. Friedberg
Journal: Blood (2012)
Hereditary Angioedema with Normal C1 Inhibitor: An Italian Case Series
Authors: Maria Bova, Valeria Bafunno, Andrea Zanichelli, Mauro Cancian, Maria Pina Barca, Tiziana Maria Angela De Pasquale, Davide Firinu, Gianni Marone, Vincenzo Montinaro, Stefano Pizzimenti, Oliviero Rossi, Chiara Suffritti, Massimo Triggiani, Alessandra Zoli, Marco Cicardi
Journal: Journal of Allergy and Clinical Immunology (2017)